Trademark: 90029109
Word
MUNA MEDICAL UTILITY NETWORK ACCREDITOR
Status Date
Monday, February 12, 2024
Filing Date
Tuesday, June 30, 2020
Published for Opposition
Tuesday, December 21, 2021
9 Downloadable software application for tracking, managing, and analyzing data for use in the testing and diagnosis of COVID-19, coronavirus, and other diseases; downloadable computer programs for tracking, managing, and analyzing data for use in the testing and diagnosis of COVID-19, coronavirus, and other diseases; downloadable software in the nature of a mobile application for tracking, managing, and analyzing data for use in the testing and diagnosis of COVID-19, coronavirus, and other diseases; downloadable software application for smartphones and tablet computers that allows users to receive data over a wireless communication network from a Polymerase Chain Reaction (PCR) testing system, save them and represent them in graphical format; downloadable software application for sending data and GPS coordinates via blockchain to a dedicated storage location in order to inform authorities about the presence of the infectious disease, and also for connecting with a Polymerase Chain Reaction (PCR) testing system in order to download testing data, plot the data, and/or automatically send the data via LTE network to a dedicated storage location for the purposes of monitoring the disease outbreak; electronic communications device for automatically uploading information over a wireless communication network to a smartphone and then wirelessly sending the information to a secure blockchain powered global network, instantly making the test results available anywhere in the world
44 Healthcare, wellness and medical services; medical services, namely, provision of clinical assessments, evaluations and diagnostic lab testing; providing healthcare, wellness information and public health information in connection with infectious disease and COVID-19; Medical testing for diagnostic or treatment purposes, namely, on-site testing for diagnosis and treatment of COVID-19, including both testing and analysis of test results; providing a website featuring medical information; providing a website featuring information in the field of antibodies for use in targeting the CCR5 cell receptor; providing health and medical information, namely, providing a website featuring information in the field of therapeutic agents, preparations and substances for the prevention and/or treatment of HIV, cancer, graft-versus-host disease, autoimmune diseases, nonalcoholic steatohepatitis, immune system related diseases and disorders, respiratory diseases and disorders, COVID-19; all of the forgoing excluding information directed to adjuvants for vaccines and molecular genetics and genomics testing and reporting; medical analysis services for diagnostic purposes; providing information relating to the testing and diagnosis of COVID-19, coronavirus, and other diseases; providing a website featuring news and information relating to the testing and diagnosis of COVID-19, coronavirus, and other diseases; charitable services, namely, providing medical devices and services for use in the testing and diagnosis of COVID-19, coronavirus, and other diseases
10 Medical device and apparatus for use in the testing and diagnosis of COVID-19, coronavirus, and viruses; medical testing and diagnostic device and apparatus for the detection of COVID-19, coronavirus, and viruses; computerized medical recording and analysis apparatus for the diagnosis of COVID-19, coronavirus, and viruses; medical device and apparatus for use in the testing and diagnosis of COVID-19, coronavirus, and viruses, which also automatically uploads the testing information over a wireless communication network to a smartphone and then wirelessly sends the information to a secure blockchain powered global network, instantly making the test results available anywhere in the world
42 Providing online non-downloadable software to track, manage, and analyze data related to employee, customer and passenger health status; platform as a services (PaaS) featuring software for rapidly reviewing and analyzing COVID-19 test results, and communicating those results; scientific research consulting services in the field of immunology; scientific research consulting services in the field of antibodies for use in targeting the CCR5 cell receptor; scientific research consulting services in the field of therapeutic agents, preparations and substances for the prevention and/or treatment of HIV, cancer, graft-versus-host disease, autoimmune diseases, nonalcoholic steatohepatitis, immune system related diseases and disorders, respiratory diseases and disorders, COVID-19; medical research services; medical research services in the field of antibodies for use in targeting the CCR5 cell receptor; medical research services in the field of therapeutic agents, preparations and substances for the prevention and/or treatment of HIV, cancer, graft-versus-host disease, autoimmune diseases, nonalcoholic steatohepatitis, immune system related diseases and disorders, respiratory diseases and disorders, COVID-19; all of the foregoing excluding medical research and scientific research consulting services directed to adjuvants for vaccines and molecular genetics and genomics testing and reporting; medical and scientific research in the field of testing and diagnosis of COVID-19, coronavirus, and other diseases; software as a service (SAAS) services featuring software for tracking, managing, and analyzing data for use in the testing and diagnosis of COVID-19, coronavirus, and other diseases
The mark consists of the wordings "MUNA" in a stylized font and "MEDICAL UTILITY NETWORK ACCREDITOR" located one under the other.
"MEDICAL UTILITY NETWORK ACCREDITOR"
Feb 13, 2024
Notice Of Approval Of Extension Request E-Mailed
Feb 12, 2024
Sou Extension 4 Granted
Feb 12, 2024
Sou Extension 4 Filed
Feb 12, 2024
Sou Teas Extension Received
Aug 16, 2023
Notice Of Approval Of Extension Request E-Mailed
Aug 14, 2023
Sou Extension 3 Granted
Aug 14, 2023
Sou Extension 3 Filed
Aug 14, 2023
Sou Teas Extension Received
Feb 17, 2023
Notice Of Approval Of Extension Request E-Mailed
Feb 15, 2023
Sou Extension 2 Granted
Feb 15, 2023
Sou Extension 2 Filed
Feb 15, 2023
Sou Teas Extension Received
Aug 17, 2022
Notice Of Approval Of Extension Request E-Mailed
Aug 15, 2022
Sou Extension 1 Granted
Aug 15, 2022
Sou Extension 1 Filed
Aug 15, 2022
Sou Teas Extension Received
Feb 15, 2022
Noa E-Mailed - Sou Required From Applicant
Dec 21, 2021
Official Gazette Publication Confirmation E-Mailed
Dec 21, 2021
Published For Opposition
Dec 1, 2021
Notification Of Notice Of Publication E-Mailed
Nov 18, 2021
Approved For Pub - Principal Register
Nov 18, 2021
Examiner's Amendment Entered
Nov 18, 2021
Notification Of Examiners Amendment E-Mailed
Nov 18, 2021
Examiners Amendment E-Mailed
Nov 18, 2021
Examiners Amendment -Written
Nov 17, 2021
Previous Allowance Count Withdrawn
Sep 14, 2021
Withdrawn From Pub - Og Review Query
Aug 27, 2021
Approved For Pub - Principal Register
Aug 10, 2021
Teas/Email Correspondence Entered
Aug 10, 2021
Correspondence Received In Law Office
Aug 10, 2021
Teas Request For Reconsideration Received
Aug 9, 2021
Notification Of Final Refusal Emailed
Aug 9, 2021
Final Refusal E-Mailed
Aug 9, 2021
Final Refusal Written
Aug 5, 2021
Teas/Email Correspondence Entered
Aug 5, 2021
Correspondence Received In Law Office
Aug 5, 2021
Teas Response To Office Action Received
Feb 5, 2021
Notification Of Non-Final Action E-Mailed
Feb 5, 2021
Non-Final Action E-Mailed
Feb 5, 2021
Non-Final Action Written
Jan 22, 2021
Assigned To Examiner
Jul 23, 2020
New Application Office Supplied Data Entered
Jul 3, 2020
New Application Entered
Trademark Alertz updated from USPTO on 2030-01-24
